SGLT2i and GLP-1RA for CVD and Kidney Disease Risk Reduction SGLT2i and GLP-1RA for CVD and Kidney Disease Risk Reduction

Despite proven efficacy in cardiovascular and kidney disease risk reduction, both SGLT-2i and GLP-1RA remain underused by cardiologists in clinical practice, according to this commentary.Circulation
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news